Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Trexquant Investment LP

Trexquant Investment LP cut its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 59.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 83,241 shares of the biopharmaceutical company's stock after selling 122,781 shares during the period. Trexquant Investment LP owned approximately 0.12% of Xencor worth $1,913,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in shares of Xencor during the third quarter valued at approximately $540,000. Barclays PLC lifted its stake in shares of Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after acquiring an additional 78,066 shares during the last quarter. Prudential Financial Inc. boosted its holdings in Xencor by 10.7% during the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company's stock valued at $1,625,000 after acquiring an additional 6,810 shares during the period. Jane Street Group LLC grew its position in Xencor by 18.6% in the 3rd quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock valued at $3,387,000 after acquiring an additional 26,473 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock worth $29,273,000 after purchasing an additional 17,658 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently commented on XNCR. Wells Fargo & Company cut their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.38.

Xencor Stock Down 1.6 %

Shares of NASDAQ XNCR traded down $0.14 during midday trading on Monday, reaching $8.40. 33,500 shares of the company's stock traded hands, compared to its average volume of 613,783. The company has a market cap of $591.88 million, a price-to-earnings ratio of -2.63 and a beta of 0.90. The stock's 50 day simple moving average is $13.07 and its 200-day simple moving average is $19.09. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.